Download the article
“Nanopharm Ltd., an Aptar Pharma company and leader in contract research and development of orally inhaled and nasally delivered drug products (OINDP), and Leyden Labs, a company targeting commonalities of viral families to protect humanity from known and future viruses, have announced an agreement to develop nasal sprays that may provide broad protection against respiratory viruses. This collaboration combines Leyden Labs’ portfolio and Nanopharm’s expertise in the development of nasally delivered drug products.
Leyden Labs’ platform targets commonalities of viral families to develop product candidates that protect against many strains of a virus simultaneously with a single product. Its easy-to-use nasal spray product candidates may allow people to immediately protect themselves against infection and transmission of known and new viruses, protecting humanity from the devastating effects of future pandemics and recurring seasonal outbreaks such as influenza and coronaviruses.
Nanopharm will screen and subsequently develop a liquid nasal spray formulation, including performance testing and nasal deposition studies, to prepare Leyden Labs for Phase 1 clinical studies. Formulation approaches utilising muco-adhesive technologies will be part of the development process to try to achieve maximum deposition and retention in the nasal cavity. In parallel, a powder system may also be assessed to provide long-term stability.
The CEOs of both companies expressed their excitement about the partnership and its potential to bring effective solutions against respiratory viruses. All formulation development will be performed at Nanopharm’s facility in Newport, United Kingdom, which houses its R&D laboratories for formulation and characterisation of inhaled and nasal products, supporting start-up biotech, big pharma or generic companies globally.”
